D
89bio, Inc. ETNB
$14.79 -$0.01-0.07% NASDAQ
Recommendation
Prev Close
$14.80
Volume
2,513,927
Avg Vol (90D)
3,543,327
Market Cap
$2.30B
Dividend & Yield
--
52-Week Range
$4.16 - $15.06
P/E (TTM)
--
EPS (TTM)
-$3.61
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
10/13/2025 - Zacks Investment Research
89BIO (NASDAQ:ETNB) Sees Unusually-High Trading Volume - Here's What Happened
10/11/2025 - MarketBeat
89bio (ETNB, $14.87) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 9, 2025
10/10/2025 - Tickeron - Stocks
89bio (ETNB, $14.81) Stochastic Oscillator left the overbought zone on October 08, 2025
10/9/2025 - Tickeron - Stocks
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89BIO (NASDAQ:ETNB)
10/8/2025 - MarketBeat
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates DAY, BRNS, ETNB, VRNT on Behalf of Shareholders
10/8/2025 - Globe Newswire
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders
10/7/2025 - PR Newswire
89bio (ETNB, $14.87) entered Uptrend as Momentum indicator ascends above 0 level on Oct 06, 2025
10/7/2025 - Tickeron - Stocks
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC ...
10/6/2025 - GuruFocus
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
10/6/2025 - Business Wire
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
10/6/2025 - Zacks Investment Research
89bio (ETNB): Exploring Valuation After 62% Share Price Surge in the Biotech Sector
10/3/2025 - Simply Wall St
89bio (ETNB, $14.84) entered Downtrend as Momentum indicator drops below 0 level on Oct 02, 2025
10/3/2025 - Tickeron - Stocks
89BIO Sees Unusually High Options Volume (NASDAQ:ETNB)
10/2/2025 - MarketBeat
89bio (ETNB, $14.69) Stochastic Oscillator left the overbought zone on October 01, 2025
10/2/2025 - Tickeron - Stocks
after courting 14 pharmas 89bio was left between roche and hard place buyout talks
10/2/2025 - FierceBiotech.com - Biotech
Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR
10/2/2025 - Nasdaq News: Markets
Roche Initiates Tender Offer for 89bio (ETNB) in $3.5B Acquisition
10/1/2025 - GuruFocus
Roche begins tender offer for 89bio as part of acquisition
10/1/2025 - Seeking Alpha - Healthcare
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash
10/1/2025 - Globe Newswire
The volume for 89bio stock increased for four consecutive days, resulting in a record-breaking daily growth of 68% of the 65-Day Volume Moving Average
10/1/2025 - Tickeron - Stocks
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal
9/30/2025 - Yahoo! Finance: News
89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal
9/30/2025 - Insider Monkey
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PINC, MTSR, ETNB on Behalf of Shareholders
9/29/2025 - PR Newswire
12 Best Performing Healthcare Stocks to Buy Right Now
9/29/2025 - Insider Monkey
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$465.64M
EBIT (TTM)
-$465.68M
Net Income (TTM)
-$450.21M
Balance Sheet
Total Assets (Q)
$603.49M
Total Debt (Q)
$37.62M
Total Liabilities (Q)
$81.75M
Book Value Per Share (Q)
$3.52
Cash Flow
Cash from Operations (TTM)
-$439.10M
Cash from Investing (TTM)
-$103.27M
Cash from Financing (TTM)
$459.23M
Net Change in Cash (TTM)
-$83.14M
Filings
Filing Date
Friday, August 8, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
2.04
7-Day Total Return
-0.40%
30-Day Total Return
60.94%
60-Day Total Return
46.29%
90-Day Total Return
48.49%
Year to Date Total Return
85.34%
1-Year Total Return
86.98%
2-Year Total Return
104.28%
3-Year Total Return
92.83%
5-Year Total Return
-38.12%
52-week Low
Apr 09, 2025 - $4.16
52-week High
Sep 18, 2025 - $15.06
Valuation
Market Cap
$2.30B - Mid Cap
Enterprise Value
$1.78B
Price/Sales (TTM)
--
Price/Book (Q)
4.21
Dividends and Shares
Shares Outstanding
157.88
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.89bio.com
Phone Number
415 432 9270
Address
655 Montgomery Street
San Francisco, CA 94111
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product... more
NASDAQ 10/14/2025 4:00PM Eastern Quotes delayed